

The Journal of PHARMACOLOGY

And Experimental Therapeutics

A Publication of the American Society for Pharmacology and Experimental Therapeutics

June 2023

Vol. 385, No. 3

Contents

VIEWPOINT

- Bath Salts to Therapies: Can Separation of Adverse and Therapeutic Effects of Substituted Cathinones Lead to a Medication for Psychostimulant Use Disorder? 159
Ellen M. Unterwald and Scott M. Rawls
- Neurochemical and Cardiovascular Effects of 4-Chloro Ring-Substituted Synthetic Cathinones in Rats 162
Michael R. Chojnacki, Eric B. Thorndike, John S. Partilla, Kenner C. Rice, Charles W. Schindler, and Michael H. Baumann

BEHAVIORAL PHARMACOLOGY

- Assessment of Abuse-Related Discriminative Stimulus Effects of Nicotine Aerosol in Rodents 171
Yasmin Alkhlaif and Keith L. Shelton
- Pharmacokinetic and Pharmacodynamic Consequences of Cytochrome P450 3A Inhibition on Mitragynine Metabolism in Rats 180
Shyam H. Kamble, Samuel Obeng, Francisco León, Luis F. Restrepo, Tamara I. King, Erin C. Berthold, Siva Rama Raju Kanumuri, Lea R. Gamez-Jimenez, Victoria L.C. Pallares, Avi Patel, Nicholas P. Ho, Aidan Hampson, Christopher R. McCurdy, Lance R. McMahon, Jenny L. Wilkerson, Abhisheak Sharma, and Takato Hiranita

DRUG DISCOVERY AND TRANSLATIONAL MEDICINE

- TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy 193
Takashi Ishikawa, Hiroe Hara, Ayumi Kawano, Kimio Tohyama, Yuichi Kajita, Yuhei Miyanozana, Tatsuki Koike, and Haruhide Kimura
- In Vivo Pharmacokinetic and Pharmacodynamic Properties of the Antiarrhythmic Molecule *ent*-Verticilide 205
Daniel J. Blackwell, Abigail N. Smith, Tri Do, Aaron Gochman, Jeffrey Schmeckpeper, Corey R. Hopkins, Wendell S. Akers, Jeffrey N. Johnston, and Bjorn C. Knollmann

ENDOCRINE AND DIABETES

- BI-Y, an Neupilin-1 Antagonist, Enhances Revascularization and Prevents Vascular Endothelial Growth Factor-A Induced Retinal Hyperpermeability in Rodent Models of Retinopathies 214
Leo Thomas, Sarah Low, Gale Hansen, Remko A. Bakker, and Nina Zippel

ERRATUM

- Correction to "Cannabinoid Tolerance in S426A/S430A x β -Arrestin 2 Knockout Double-Mutant Mice" 222

Supplemental material is available at jpet.aspetjournals.org.

About the cover: BI-Y antagonizes the biological effects of Nrp-1, thus also Sema3A and partially VEGF, promoting revascularization and reducing hyperpermeability. See the article by Thomas et al. ([dx.doi.org/10.1124/jpet.122.001473](https://doi.org/10.1124/jpet.122.001473)).